LHCG vs. CHE: Which Stock Is the Better Value Option?
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of El Pollo Loco Holdings, Inc....
Style Box ETF report for VIOG
New Strong Buy Stocks for May 21st
Illumina (ILMN) gains ground on product launches and international prospects.
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).
CryoLife's (CRY) shares gain on growth in all product lines along with strong performance in all geographies in Q1.
Despite the bottom line of Orthofix (OFIX) betters estimates, the company's shares drop due to trimmed 2018 earnings outlook.
Chemed (CHE) sees a stellar Q1 backed by steady year-over-year revenue growth in both of its subsidiaries.
SmarTrend identified an Uptrend for Chemed Corp (NYSE:CHE) on March 5th, 2018 at $264.77. In approximately 2 months, Chemed Corp has returned 23.32% as of today's recent price of $326.50.
BioScrip's (BIOS) shift in strategy to raise core revenue mix hampers growth in Q1. Year-over-year rise in core product mix buoys optimism.
Favorable underlying market trends along with a slew of new product and service offerings by STERIS (STE) instill confidence in investors.
Wright Medical's (WMGI) Q1 results solid; growth in upper and lower extremities segments encourages.
Continued generation of new business and geographical expansion drive Haemonetics' (HAE) Q4 results.
Penumbra (PEN) benefits from strong growth across all geographies and product lines in Q1.
Luminex (LMNX) gains on ARIES and VERIGENE platforms in Q1; a solid guidance encourages.
Myriad Genetics' (MYGN) Q3 revenues decline year over year. Strong demand for GeneSight, Vectra DA and Prolaris tests was encouraging.
We currently await the completion of Henry Schein's (HSIC) planned spin-off of global Animal Health business. This business contributes nearly 30% to the company's top line.
Robust growth in Medicare and non-Medicare revenues at Amedisys' (AMED) Home Health and Hospice divisions boost the company's Q1 results.